Levofloxacin treatment of active tuberculosis and the risk of adverse events

Chest

Volumn 128, Issue 3, 2005, Pages 1406-1413

  Marra, Fawziah ^a,b   Marra, Carlo A ^a   Moadebi, Susanne ^b   Shi, Peilin ^a   Elwood, R Kevin ^a   Stark, Greg ^b   FitzGerald, J Mark ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Adverse events; Fluoroquinolones; Levofloxacin; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG INDICATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RESISTANCE; LUNG TUBERCULOSIS; MALE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 24944456673     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1406     Document Type: Article

References (42)

1. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282:677-686
2. World Health Organization. WHO report 2003: global tuberculosis control. Report WHO/CDS/TB/2003-316. Available at: http://www.who.int/gtb/publications/ globrep/index.html. Accessed July 19, 2005
3. CDC. Reported tuberculosis in the United States, 2002. Atlanta, GA: US Department of Health and Human Services CDC, 2003
4. Advisory Council on the Elimination of Tuberculosis (ACET). Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Morb Mortal Wkly Rep 1999; 48:1-13
5. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662
6. Crofton J, Choculet P, Maher D. WHO Report 1997: guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; WHO/TB/1996-210
7. Gleissberg V. The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable? Lancet 1999; 353: 998-999
8. Snider DE, Castro KG. The global threat of drug-resistant tuberculosis. N Engl J Med 1998; 338:1689-1690
9. Garcia-Rodriguez JA, Gomez Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32:797-808
10. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999; 58(suppl):19-22
11. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38:1161-1164
12. Klemens SP, Sharpe CA, Rogge MC, et al. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38:1476-1479
13. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 2004; 16:334-336
14. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 169:421-426
15. Peloquin CA, Berning SE, Huitt GA, et al. Levofloxacin for drug-resistant Mycobacterium tuberculosis. Ann Pharmacother 1998; 32:268-269
16. Pletz MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780-782
17. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477
18. Schberg T, Rebhan K, Lode H. Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026-2030
19. Myers RH, Montgomery DC, Vinig GG. Generalized linear model: with applications in engineering and the sciences. New York, NY: John Wiley & Sons, 2002
20. Chaisson RE. Tuberculosis chemotherapy: still a double-edged sword: Am J Respir Crit Care Med 2003; 167:1461-1462
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170
23. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34:187-220
24. Hong Kong Chest Service/BMJ Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992; 73:59-67
25. Kohno S, Koga H, Kaku M, et al. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102:1815-1818
26. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45:859-870
27. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124:1476-1481
28. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993; 104:1194-1198
29. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148:1547-1551
30. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995; 21:79-83
31. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156:901-905
32. El-Sadr WM, Perhnan DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis: Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26:1148-1158
33. Telzak EE, Chirgwin KD, Nelson ET, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens: Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999; 3:337-343
34. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61:9-18
35. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3:432-442
36. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis [letter]. N Engl J Med 1994; 330:1241
37. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis in health-care workers following exposure to rifampin-isoniazid-streptomycin-ethambutol-resistant tuberculosis. Infect Dis Clin Pract 1995; 4:219-225
38. Ridzon R, Meador J, Maxwell R, et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997; 24:1264-1265
39. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of multidrug-resistant tuberculosis. Can Med Assoc J 2002; 167:131-136
40. Lou H-X, Shallo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug resistant tuberculosis prophylaxis in solid organ transplant population. Pharmacotherapy 2002; 22:701-704
41. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12:551-558
42. Hernandez-Garduno E, Cook V, Kunimoto D, et al. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004; 59:286-290